Argos Therapeutics, Inc. – Product Pipeline Review – Q1 2011

Document Sample
Argos Therapeutics, Inc. – Product Pipeline Review – Q1 2011 Powered By Docstoc
					  Argos Therapeutics, Inc. – Product Pipeline Review –
                        Q1 2011
                                                                                          Reference Code: GMDHC1210CDB

                                                                                                Publication Date: MAY 2011




Argos Therapeutics, Inc. – Product Pipeline Review – Q1 2011                                GMDHC1210CDB / Published MAY 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Argos Therapeutics, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Argos Therapeutics, Inc. Snapshot                                                                                     5
    Argos Therapeutics, Inc. Overview                                                                                 5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Argos Therapeutics, Inc. – Research and Development Overview                                                          6
    Key Therapeutic Areas                                                                                             6
Argos Therapeutics, Inc. – Pipeline Review                                                                            8
    Pipeline Products by Stage of Development                                                                         8
    Pipeline Products – Monotherapy                                                                                   9
    Pipeline Products – Combination Treatment Modalities                                                             10
Argos Therapeutics, Inc. – Pipeline Products Glance                                                                  11
    Argos Therapeutics, Inc. Clinical Stage Pipeline Products                                                        11
         Phase II Products/Combination Treatment Modalities                                                          11
         Phase I Products/Combination Treatment Modalities                                                           12
    Argos Therapeutics, Inc.–Early Stage Pipeline Products                                                           13
         Pre-Clinical Products/Combination Treatment Modalities                                                      13
Argos Therapeutics, Inc. – Drug Profiles                                                                             14
    AGS-003                                                                                                          14
         Product Description                                                                                         14
         Mechanism of Action                                                                                         14
         R&D Progress                                                                                                14
    AGS-003 + Sunitinib                                                                                              15
         Product Description                                                                                         15
         Mechanism of Action                                                                                         15
         R&D Progress                                                                                                15
    AGS-004                                                                                                          17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    AGS-009                                                                                                          18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    AGS-009                                                                                                          19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    CD83 Soluble Protein                                                                                             20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20
         R&D Progress                                                                                                20
Argos Therapeutics, Inc. – Pipeline Analysis                                                                         21
    Argos Therapeutics, Inc. – Pipeline Products by Therapeutic Class                                                21




Argos Therapeutics, Inc. – Product Pipeline Review – Q1 2011                              GMDHC1210CDB / Published MAY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Argos Therapeutics, Inc. – Product Pipeline Review



    Argos Therapeutics, Inc. - Pipeline Products By Target                                                           22
    Argos Therapeutics, Inc. – Pipeline Products by Route of Administration                                          24
    Argos Therapeutics, Inc. – Pipeline Products by Molecule Type                                                    25
Argos Therapeutics, Inc. – Recent Pipeline Updates                                                                   26
Argos Therapeutics, Inc. - Dormant Projects                                                                          28
Argos Therapeutics, Inc. – Locations And Subsidiaries                                                                29
    Head Office                                                                                                      29
Financial Deals Landscape                                                                                            30
    Argos Therapeutics, Inc., Deals Volume Summary, 2004 to YTD 2011                                                 30
    Argos Therapeutics, Inc., Deals Summary By Region, 2004 to YTD 2011                                              31
    Argos Therapeutics, Inc., Deals Summary, 2004 to YTD 2011                                                        32
    Argos Therapeutics, Inc. Detailed Deal Summary                                                                   33
         Venture Financing                                                                                           33
         Argos Therapeutics Secures $35 Million In Series C Financing                                                33
         Merix Enters Into Co-Development Agreement With Kirin                                                       36
         Licensing Agreements                                                                                        37
         Argos Therapeutics Enters Into Licensing Agreement With Therakos                                            37
         Argos Therapeutics Enters Into Licensing Agreement With Beckman Coulter                                     38
         Novo Nordisk Enters Into License Agreement With Argos Therapeutics                                          39
Appendix                                                                                                             40
    Methodology                                                                                                      40
         Coverage                                                                                                    40
         Secondary Research                                                                                          40
         Primary Research                                                                                            40
         Expert Panel Validation                                                                                     41
    Contact Us                                                                                                       41
    Disclaimer                                                                                                       41




Argos Therapeutics, Inc. – Product Pipeline Review – Q1 2011                              GMDHC1210CDB / Published MAY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(3)
Argos Therapeutics, Inc. – Product Pipeline Review




Lis t o f Ta b le s
Argos Therapeutics, Inc. – Pipeline by Therapy Area and Indication, 2011                                                                                                                     7

Argos Therapeutics, Inc. – Pipeline by Stage of Development, 2011                                                                                                                            8

Argos Therapeutics, Inc. – Monotherapy Products in Pipeline, 2011                                                                                                                            9

Argos Therapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2011                                                                                                              10

Argos Therapeutics, Inc. - Phase II, 2011                      
				
DOCUMENT INFO
Description: Argos Therapeutics, Inc. – Product Pipeline Review – Q1 2011 Summary Global Market Direct’s pharmaceuticals report, “Argos Therapeutics, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Argos Therapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Argos Therapeutics, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Argos Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Argos Therapeutics, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Argos Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Argos Therapeutics, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Argos Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit i
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries